Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion

Kamaguchi, Mayumi; Iwata, Hiroaki; Mori, Yuiko; Toyonaga, Ellen; Ujiie, Hideyuki; Kitagawa, Yoshimasa; Shimizu, Hiroshi

Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion

Kamaguchi, Mayumi; Iwata, Hiroaki; Mori, Yuiko et al.

Frontiers in immunology, 2017, 8, 1669

Permalink : https://hdl.handle.net/2115/68212

このアイテムのアクセス数:1,141件（2026-10-07 19:03 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
immu-08-01669	pdf	2.44 MB	565

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/68212
タイトル	Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion
著者	Kamaguchi, Mayumi ; Iwata, Hiroaki ; Mori, Yuiko ; Toyonaga, Ellen ; Ujiie, Hideyuki ; Kitagawa, Yoshimasa ; Shimizu, Hiroshi
著者名 Kamaguchi, Mayumi
e-Rad_Researcher 20397334 著者名 Iwata, Hiroaki
著者名 Mori, Yuiko
著者名 Toyonaga, Ellen
e-Rad_Researcher 60374435 著者名 Ujiie, Hideyuki
e-Rad_Researcher 00224957 著者名 Kitagawa, Yoshimasa
e-Rad_Researcher 00146672 著者名 Shimizu, Hiroshi
言語	英語
キーワード	bullous pemphigoid
	type XVII collagen
	intravenous immunoglobulin
	idiotypic antibody
	depletion
	autoantibody
発行日	2017-11-27
出版者	Frontiers Media
収録物名	Frontiers in immunology
巻(号)	8
ページ	1669
抄録	Bullous pemphigoid (BP) mainly targets type XVII collagen (COL17). Intravenous immunoglobulin (IVIg) is used to treat numerous autoimmune diseases, including BP. The major mechanism of action for IVIG is thought to be its immunomodulatory effect. However, little is known about the precise mechanisms of IVIg in BP. We investigate the cellular effects of IVIg, toward treatments for BP. Keratinocytes were treated with IgG from BP patients (BP-IgG) and with IVIg, and then the COL17 expression was detected by Western blotting. Cell adhesion and ex vivo dermal-epidermal separation were also investigated for the condition with BP-IgG and IVIg. BP-IgG targeting the non-collagenous 16A domain induces the depletion of COL17 in cultured keratinocytes (DJM-1 cells). The COL17 levels in DJM-1 cells were decreased by 50% after 4 h of BP-IgG stimulation as determined by Western blotting. By contrast, BP-IgG with IVIg was found to result in 70-90% increases in COL17 and to restore adhesion to the plate. Interestingly, IVIg significantly inhibited the binding of BP-IgG to the COL17-enzymelinked immunosorbent assay plate, and this was due to anti-idiotypic antibodies against BP-IgG. When anti-idiotypic antibodies against BP-IgG in 0.02% of IVIg were depleted from IVIg, those antibodies did not exhibit inhibitory effects on COL17 depletion. When cryosections of human skin were incubated with BP-IgG in the presence of leukocytes, dermal-epidermal separation was observed. BP-IgG treatment with IVIg or anti-idiotypic antibodies did not induce such separation. These findings strongly suggest the presence of anti-idiotypic antibodies against anti-COL17 IgG in IVIg. This mechanism of IVIg could be a target for therapies against BP.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
権利情報	© 2017 Kamaguchi, Iwata, Mori, Toyonaga, Ujiie, Kitagawa and Shimizu.
PISSN	1664-3224
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.3389/fimmu.2017.01669